{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Toxo IgM II",
        "LIAISON\u00ae Control Toxo IgM II"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K131441",
    "Predicate Device Reference 510(k) Number(s)": [
        "K001707"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LGD"
    ],
    "Summary Letter Date": "May 17, 2013",
    "Summary Letter Received Date": "May 20, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3780"
    ],
    "Regulation Name(s)": [
        "Toxoplasma gondii Serological Reagent"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "serology",
        "parisitology"
    ],
    "Analyte(s)": [
        "IgM antibodies to Toxoplasma gondii"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Antibody capture chemiluminescence immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Toxo IgM II and Control Toxo IgM II qualitative CLIA assay to detect Toxoplasma gondii IgM antibodies in human serum",
    "Indications for Use Summary": "Qualitative determination of IgM antibodies to Toxoplasma gondii in human serum as an aid in the presumptive diagnosis of acute or recent infection, including in pregnant women, recommended with an IgG assay; not cleared for blood/plasma donor screening.",
    "fda_folder": "Microbiology"
}